Roivant Sciences Ltd.
ROIV
Positions held
Your positionsROIV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Roivant Sciences is positioned in the rapidly growing biotechnology sector, focusing on innovative therapies that address unmet medical needs.
- The company's target mean price is $48.08, indicating significant upside potential from its current valuation.
- Despite recent challenges, Roivant's gross margin was 80.3% in Q2 2026, showcasing strong product profitability.
- The biotechnology industry is highly competitive, with many companies vying for market share and funding.
- Roivant's revenue decreased by 43% in Q2 2026 compared to the previous quarter, dropping from $2.5M to $1.4M.
- The company reported an operating margin of -25408.1% in Q2 2026, reflecting severe operational challenges.
Fundamentals
| Market cap | $24.71B | Enterprise value | $21.67B | Trailing P/E | — | Forward P/E | -19.92 |
| PEG | — | Price / book | 5.84 | Beta | 1.10 | Dividend yield | 0.00% |
| Revenue growth | -33.5% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -254.1% |
| Profit margin | 0.0% | ROE | -8.5% | ROA | -16.5% | Debt / equity | 0.02 |
| Current ratio | 16.72 | Free cash flow | -$1.13B | Analyst recommendation | strong_buy | Mean target | $48.08 |
| 52w high | $42.50 | 52w low | $15.90 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M | — |
| Op margin | -25408.1% | -14087.1% | -16966.1% | -19492.9% | -13130.0% | — |
| Net income | -$190M | $303M | -$266M | -$114M | -$223M | — |
| Gross margin | 80.3% | 87.3% | 65.0% | 92.9% | 92.9% | — |
| Gross profit | $1.2M | $2.2M | $1.3M | $1.5M | $2.0M | — |
| Operating income | -$366M | -$355M | -$339M | -$306M | -$285M | — |
- Revenue -43% vs prior quarter ($1.4M vs $2.5M).
- Gross margin 80.3% (was 87.3% prior quarter).
- Operating margin compressed to -25408.1%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | — |
| Op margin | -15560.6% | -3833.3% | -2521.7% | -2565.9% | — |
| Net income | -$300M | -$172M | $4.3B | -$1.0B | — |
| Gross margin | 84.4% | 96.9% | 95.1% | 90.4% | — |
| Gross profit | $7.0M | $28.1M | $31.1M | $28.5M | — |
| Operating income | -$1.3B | -$1.1B | -$825M | -$809M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
2026-09-28 · Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
2026-09-24 · Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
2026-09-23 · Sector Update: Healthcare Stocks Retreat in Afternoon Trading
2026-09-23 · Sector Update: Healthcare Stocks Mixed Premarket Wednesday
2026-09-23 · Sector Update: Healthcare
2026-09-23 · Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
2026-09-23 · Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus
2026-09-23 · Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
2026-09-22 · Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
2026-09-18 · What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
2026-09-13 · Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
Price (daily)
Full chart · RSI · MACD · patterns